|
1
|
Gwyther SJ and Schwartz LH: How to assess
anti-tumour efficacy by imaging techniques. Eur J Cancer. 44:39–45.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Contractor KB and Aboagye EO: Monitoring
predominantly cytostatic treatment response with 18F-FDG PET. J
Nucl Med. 50 Suppl 1:97S–105S. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Bazelaire C, Alsop DC, George D,
Pedrosa I, Wang Y, Michaelson MD and Rofsky NM: Magnetic resonance
imaging-measured blood flow change after antiangiogenic therapy
with PTK787/ZK 222584 correlates with clinical outcome in
metastatic renal cell carcinoma. Clin Cancer Res. 14:5548–5554.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Padhani AR, Krohn KA, Lewis JS and Alber
M: Imaging oxygenation of human tumours. Eur Radiol. 17:861–872.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carmetliet P: Mechanisms of angiogenesis
and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kerbel RS: Antiangiogenic therapy: A
universal chemosensitization strategy for cancer? Science.
312:1171–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murphy DA, Makonnen S, Lassoued W, Feldman
MD, Carter C and Lee WM: Inhibition of tumor endothelial ERK
activation, angiogenesis, and tumor growth by sorafenib
(BAY43-9006). Am J Pathol. 169:1875–1885. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thorpe PE: Vascular targeting agents as
cancer therapeutics. Clin Cancer Res. 10:415–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kessler T, Schwöppe C, Liersch R,
Schliemann C, Hintelmann H, Bieker R, Berdel WE and Mesters RM:
Generation of fusion proteins for selective occlusion of tumor
vessels. Curr Drug Discov Technol. 5:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samad F and Ruf W: Inflammation, obesity,
and thrombosis. Blood. 122:3415–3422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eisenreich A: Regulation of vascular
function on posttranscriptional level. Thrombosis. 2013:9487652013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bieker R, Kessler T, Schwöppe C, Padró T,
Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W,
Mesters RM and Berdel WE: Infarction of tumor vessels by
NGR-peptide directed targeting of tissue factor. Experimental
results and first-in-man experience. Blood. 113:5019–5027. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nilsson F, Kosmehl H, Zardi L and Neri D:
Targeted delivery of tissue factor to the ED-B domain of
fibronectin, a marker of angiogenesis, mediates the infarction of
solid tumors in mice. Cancer Res. 61:711–716. 2001.PubMed/NCBI
|
|
14
|
Liu C, Huang H and Doñate F:
Prostate-specific membrane antigen directed selective thrombotic
infarction of tumors. Cancer Res. 62:5470–5475. 2002.PubMed/NCBI
|
|
15
|
Hu P, Yan J, Sharifi J, Bai T, Khawli LA
and Epstein AL: Comparison of three different targeted tissue
factor fusion proteins for inducing tumor vessel thrombosis. Cancer
Res. 63:5046–5053. 2003.PubMed/NCBI
|
|
16
|
Schwöppe C, Kessler T, Persigehl T,
Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel
W, Mesters RM and Berdel WE: Tissue-factor proteins induce
occlusion of tumor vessels. Thromb Res. 125 Suppl 2:S143–S150.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pasqualini R, Koivunen E, Kain R,
Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W
and Ruoslahti E: Aminopeptidase N is a receptor for tumor-homing
peptides and a target for inhibiting angiogenesis. Cancer Res.
60:722–727. 2000.PubMed/NCBI
|
|
18
|
Kessler T, Bieker R, Padró T, Schwöppe C,
Persigehl T, Bremer C, Kreuter M, Berdel WE and Mesters RM:
Inhibition of tumor growth by RGD peptide-directed delivery of
truncated tissue factor to the tumor vasculature. Clin Cancer Res.
11:6317–6324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Persigehl T, Ring J, Bremer C, Heindel W,
Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst
C, et al: Non-invasive monitoring of tumor-vessel infarction by
retargeted truncated tissue factor tTF-NGR using multi-modal
imaging. Angiogenesis. 17:235–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Persigehl T, Matuszewski L, Kessler T,
Wall A, Meier N, Ebert W, Berdel WE, Heindel W, Mesters R and
Bremer C: Prediction of antiangiogenic treatment efficacy by iron
oxide enhanced parametric magnetic resonance imaging. Invest
Radiol. 42:791–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sabach AS, Bruno M, Kim D, Mulholland T,
Lee L, Kaura S and Lim RP: Gadofosveset trisodium: Abdominal and
peripheral vascular applications. AJR Am J Roentgenol.
200:1378–1386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schwöppe C, Zerbst C, Fröhlich M,
Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R,
Stypmann J, Dreiling A, et al: Anticancer therapy by tumor vessel
infarction with polyethylene glycol conjugated retargeted tissue
factor. J Med Chem. 56:2337–2347. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Persigehl T, Bieker R, Matuszewski L, Wall
A, Kessler T, Kooijman H, Meier N, Ebert W, Berdel WE, Heindel W,
et al: Antiangiogenic tumor treatment: Early noninvasive monitoring
with USPIO-enhanced MR imaging in mice. Radiology. 244:449–456.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stucke-Ring J, Ronnacker J, Brand C,
Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V,
Hintelmann H, et al: Combinatorial effects of doxorubicin and
retargeted tissue factor tTF-NGR by intratumoral entrapment of
doxorubicin and proapoptotic increase of tumor vascular infarction.
Oncotarget. 7:82458–82472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Höink AJ, Heindel W and Buerke B:
Radiological evaluation of the therapeutic response of malignant
diseases: Status quo, innovative developments and requirements for
radiology. Rofo. 186:927–936. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zweifel M and Padhani AR: Perfusion MRI in
the early clinical development of antivascular drugs: Decorations
or decision making tools? Eur J Nucl Med Mol Imaging. 37 (Suppl
1):S164–S182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salmon BA, Salmon HW and Siemann DW:
Monitoring the treatment efficacy of the vascular disrupting agent
CA4P. Eur J Cancer. 43:1622–1629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y,
Park J, Kiefer B, Kim C, Han JK and Choi BI: Vascular disrupting
effect of CKD-516: Preclinical study using DCE-MRI. Invest New
Drugs. 31:1097–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
European Medicines Agency: EMA's final
opinion confirms restrictions on use of linear gadolinium agents in
body scans. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/07/news_detail_002780.jsp&mid=WC0b01ac058004d5c1Jul.
21. 2017
|
|
31
|
Rezai P, Pisaneschi MJ, Feng C and Yaghmai
V: A radiologist's guide to treatment response criteria in
oncologic imaging: Functional, molecular, and disease-specific
imaging biomarkers. AJR Am J Roentgenol. 201:246–256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thoeny HC and Ross BD: Predicting and
monitoring cancer treatment response with diffusion-weighted MRI. J
Magn Reson Imaging. 32:2–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
